Asahi Songwon

- The company does not plan any major capex in the near term, which reduces the immediate need for large fundraising. - Current strategy focuses on deleveraging by using strong cash generation to retire debt. Total debt equity dropped from 0.75 to 0.55 and is targeted to go below 0.5. - EBITDA to debt ratio is improving and likely to drop below 2 in the coming year. - Once full capacity utilization and growth materialize over the next 1-2 years, free cash may be deployed for growth capex. - No explicit mention of new equity fundraising was made. - Overall, short-term focus is on reducing debt and improving cash flow without raising new funds. Longer-term capital raising may be considered when growth and capacity utilization call for significant investments.

- Current capex of about ₹5 crores has been completed, which includes adding about 40 tons to existing yellow pigment capacity with new Chinese equipment (Page 5). - No major new capex planned in the short term for existing businesses like pregabalin or AZO; focus will be on utilizing current capacities (Pages 15, 16). - Longer-term plans involve possible new CapEx after achieving better utilization and deleveraging (Page 17). - Strategy includes launching new API products over the next 1-2 years with backward integration planned for some molecules, but this will be phased and dependent on product success and scale (Pages 9, 11). - Tariff opportunities may help scale AZO exports and business, aiding margin improvement, but this does not appear to require significant immediate capex (Pages 6, 16).

- Targeting 15% sales growth over the next 1-2 years (Page 16, Page 12). - Capacity utilization expected to reach 100% over the next two years (Page 20). - Maximum top line from current capacity estimated at about ₹750 crores (Page 19). - AZO segment capacity utilization to improve from 64% to around 80-85%, with top line growth from ₹70 crores to ₹90 crores (~26-27% growth) (Page 16). - API business volumes increased by 25% despite price pressures (Page 7). - Overall top line growth expected to be decent, driven by volume and efficiency improvements (Page 12-13). - Pigments business growth expected to be modest; blue segment at maximum sustainable capacity with limited growth (Page 18, Page 19). - Export share in ATC expected to grow from 10% to 20-25% this year, driving revenue increase (Page 6).

- Targeting 15% top-line (sales) growth over the next 1-2 years. - EBITDA growth expected at around 25%, outperforming sales growth due to capacity utilization improvements and operational efficiencies. - Consolidated EBITDA margin targeted at approximately 12%, up from current levels. - PBT (Profit Before Tax) growth projected between 50-65% for FY25-26. - ROCE (Return on Capital Employed) aimed to improve from around 10-11% to 15% over the next couple of years. - Capacity utilization to reach 100% in 1-2 years, supporting top-line growth up to about 750 crores from current capacity. - API and AZO segments expected to see EBITDA margin expansion, with AZO EBITDA margin improving from marginally positive to 8-10%. - Positive cash flows expected to be used for debt reduction initially, with potential future capex for growth after deleveraging.

- The transcript on page 20 does not explicitly mention the exact current or expected order book value or detailed pending orders. - It is indicated that the company has received approvals from a few large export clients and expects to execute at least two large customer orders commercially during the current year. - The execution of large orders will be gradual through the upcoming quarters, moving towards commercial large quantity orders by year-end. - Capacity utilization is targeted to increase to 100% over the next 1-2 years to support this growth. - The expected maximum top-line from current capacity is around ₹750 crores. - The AZO segment aims to grow from ₹70 crores to ₹90 crores in revenue this year, with capacity utilization improving to around 80-85%.